Valuation United Therapeutics Corporation

Equities

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
536.12 ^USD	+0.62%		+12.12%	+10.03%

03-12	Sleep Number Corporation Appoints Kelly F. Baker as Principal Accounting Officer, Effective March 11, 2026	CI
03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	9,731	12,674	10,333	15,752	20,979	23,497	-	-
Change	-	30.24%	-18.47%	52.44%	33.18%	12%	-	-
Enterprise Value (EV) ¹	9,637	12,513	8,039	12,785	18,059	18,873	17,560	16,104
Change	-	29.85%	-35.75%	59.04%	41.25%	4.5%	-6.96%	-8.29%
P/E ratio	21.5x	18.5x	11.1x	14.3x	17.5x	19x	16.6x	14.4x
PBR	2.67x	2.67x	1.73x	2.47x	3x	2.31x	2.01x	1.76x
PEG	-	0.4x	0.3x	0.6x	1.3x	16.12x	1.1x	1x
Capitalization / Revenue	5.77x	6.55x	4.44x	5.47x	6.59x	7.03x	6.21x	5.45x
EV / Revenue	5.72x	6.46x	3.45x	4.44x	5.67x	5.64x	4.64x	3.74x
EV / EBITDA	15.9x	12.1x	6.49x	8.82x	11.4x	10.9x	9.36x	7.88x
EV / EBIT	17.3x	12.8x	6.78x	9.28x	12.1x	11.8x	9.44x	7.58x
EV / FCF	20.2x	18.9x	10.8x	11.8x	17.4x	14.7x	11.7x	9.32x
FCF Yield	4.95%	5.3%	9.3%	8.45%	5.76%	6.79%	8.53%	10.7%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	10.06	15	19.81	24.64	27.86	28.19	32.39	37.17
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	1,686	1,936	2,328	2,877	3,183	3,344	3,783	4,310
EBITDA ¹	605.8	1,031	1,238	1,450	1,578	1,735	1,877	2,043
EBIT ¹	555.9	979.7	1,185	1,377	1,492	1,601	1,860	2,125
Net income ¹	475.8	727.3	984.8	1,195	1,335	1,334	1,551	1,782
Net Debt ¹	-94.8	-161.2	-2,294	-2,967	-2,920	-4,624	-5,937	-7,392
Reference price ²	216.08	278.09	219.89	352.84	487.25	536.12	536.12	536.12
Nbr of stocks (in thousands)	45,037	45,577	46,994	44,645	43,057	43,828	-	-
Announcement Date	24/02/22	22/02/23	21/02/24	26/02/25	25/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
UNITED THERAPEUTICS CORPORATION	19.02x	5.64x	10.88x	-.--%	23.5B
ELI LILLY AND COMPANY	28.95x	10.91x	21.91x	0.67%	880B
JOHNSON & JOHNSON	25.63x	5.96x	16.23x	2.19%	582B
ABBVIE INC.	24x	6.55x	13.15x	3.16%	388B
ROCHE HOLDING AG	17.32x	4.22x	10.43x	3.13%	324B
ASTRAZENECA PLC	23.94x	4.99x	13.83x	1.75%	295B
NOVARTIS AG	20.93x	5.64x	13.96x	2.87%	293B
MERCK & CO., INC.	27.02x	4.74x	14.82x	2.92%	286B
AMGEN INC.	24.64x	6.26x	11.14x	2.74%	197B
GILEAD SCIENCES, INC.	20.1x	6.12x	11.06x	2.25%	180B
Average	23.15x	6.10x	13.74x	2.17%	344.97B
Weighted average by Cap.	24.69x	6.94x	15.68x	2.1%